Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) EBIT (2019 - 2025)

Historic EBIT for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$315.3 million.

  • Revolution Medicines' EBIT fell 7942.37% to -$315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 5876.57%. This contributed to the annual value of -$689.5 million for FY2024, which is 4153.23% down from last year.
  • Revolution Medicines' EBIT amounted to -$315.3 million in Q3 2025, which was down 7942.37% from -$264.7 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' EBIT ranged from a high of -$37.4 million in Q1 2021 and a low of -$315.3 million during Q3 2025
  • Moreover, its 5-year median value for EBIT was -$108.8 million (2023), whereas its average is -$128.6 million.
  • In the last 5 years, Revolution Medicines' EBIT plummeted by 1661.97% in 2022 and then plummeted by 19167.36% in 2023.
  • Over the past 5 years, Revolution Medicines' EBIT (Quarter) stood at -$52.9 million in 2021, then fell by 16.62% to -$61.7 million in 2022, then crashed by 191.67% to -$180.0 million in 2023, then fell by 20.18% to -$216.3 million in 2024, then crashed by 45.75% to -$315.3 million in 2025.
  • Its EBIT was -$315.3 million in Q3 2025, compared to -$264.7 million in Q2 2025 and -$240.8 million in Q1 2025.